Fate Therapeutics (FATE) Non-Current Assets (2012 - 2026)

Fate Therapeutics has reported Non-Current Assets for 15 years, with the latest figure at $105.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 29.95% year-over-year to $105.4 million; the trailing twelve-month figure through Mar 2026 stood at $479.3 million (down 30.87% YoY), and the FY2025 full-year result was $110.2 million, down 25.91% from the prior year.
• Non-Current Assets for Q1 2026 stood at $105.4 million, down from $110.2 million in the prior quarter.
• The five-year high for Non-Current Assets was $259.3 million in Q1 2022, with the low at $105.4 million in Q1 2026.
• Historically, Non-Current Assets has averaged $174.8 million across 5 years, with a median of $179.6 million in 2023.
• Annual changes were most pronounced in 2024 — Non-Current Assets advanced 8.75% — and 2025, when it plunged 33.71%.
• Fate Therapeutics' Non-Current Assets stood at $203.5 million in 2022, then dropped by 14.16% to $174.7 million in 2023, then retreated by 14.82% to $148.8 million in 2024, then fell by 25.91% to $110.2 million in 2025, then retreated by 4.39% to $105.4 million in 2026.
• The last three Non-Current Assets figures came in at $105.4 million (Q1 2026), $110.2 million (Q4 2025), and $122.4 million (Q3 2025), per Business Quant data.